Pentona

Pentona may be available in the countries listed below.

Ingredient matches for Pentona

Mazaticol

Mazaticol hydrochloride (a derivative of Mazaticol) is reported as an ingredient of Pentona in the following countries:

• Japan

International Drug Name Search

Axert

Axert is a brand name of almotriptan, approved by the FDA in the following formulation(s):

AXERT (almotriptan malate - tablet; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: May 7, 2001
  
  Strength(s): EQ 12.5MG BASE ^[RLD], EQ 6.25MG BASE
  

Has a generic version of Axert been approved?

No. There is currently no therapeutically equivalent version of Axert available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Axert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Indole derivatives
  Patent 5,565,447
  Issued: October 15, 1996
  Inventor(s): Forner; Dolors F. & Duran; Carles P. & Soto; Jose P. & Noverola; Armando V. & Mauri; Jacinto M.
  Assignee(s): Laboratorios Almirall S.A.
  A compound of formula (I) ##STR1## wherein R.sup.1 and R.sup.2 each represents a hydrogen atom or an alkyl group, Z represents a ring selected from: ##STR2## in which n represents 4, 5 or 6; ##STR3## in which R.sup.3 represents hydrogen or an alkyl group and R.sup.4 represents an alkyl, methoxy benzyl or R.sup.5 NHCO group, R.sup.5 being an alkyl group; and ##STR4## in which R.sup.6 represents an alkyl group. and pharmaceutically acceptable salts thereof are useful in the treatment of migraine and other conditions. They are prepares by decarboxylation of the corresponding indolyl 2-carboxylic acid.
  
  Patent expiration dates:
  
  
  • May 7, 2015
    
    ✓ 
    Patent use: TREATMENT OF MIGRAINE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 7, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Axert Consumer Information (Wolters Kluwer)
• Axert Consumer Information (Cerner Multum)
• Axert Advanced Consumer Information (Micromedex)
• Axert AHFS DI Monographs (ASHP)
• Almotriptan Consumer Information (Wolters Kluwer)
• Almotriptan Consumer Information (Cerner Multum)
• Almotriptan Advanced Consumer Information (Micromedex)
• Almotriptan Malate AHFS DI Monographs (ASHP)

Omeprazol Arrow

Omeprazol Arrow may be available in the countries listed below.

Ingredient matches for Omeprazol Arrow

Omeprazole

Omeprazole is reported as an ingredient of Omeprazol Arrow in the following countries:

• Sweden

International Drug Name Search

Spamilan

Spamilan may be available in the countries listed below.

Ingredient matches for Spamilan

Buspirone

Buspirone hydrochloride (a derivative of Buspirone) is reported as an ingredient of Spamilan in the following countries:

• Poland

International Drug Name Search

Reumacide

Reumacide may be available in the countries listed below.

Ingredient matches for Reumacide

Indometacin

Indometacin is reported as an ingredient of Reumacide in the following countries:

• Portugal

International Drug Name Search

Neostigmin SAD

Neostigmin SAD may be available in the countries listed below.

Ingredient matches for Neostigmin SAD

Neostigmine

Neostigmine bromide (a derivative of Neostigmine) is reported as an ingredient of Neostigmin SAD in the following countries:

• Denmark

International Drug Name Search

Cloron

Cloron may be available in the countries listed below.

Ingredient matches for Cloron

Clonazepam

Clonazepam is reported as an ingredient of Cloron in the following countries:

• Bangladesh

International Drug Name Search

Witgen

Witgen may be available in the countries listed below.

Ingredient matches for Witgen

Memantine

Memantine hydrochloride (a derivative of Memantine) is reported as an ingredient of Witgen in the following countries:

• Taiwan

International Drug Name Search

Exodril

Exodril may be available in the countries listed below.

Ingredient matches for Exodril

Naftifine

Naftifine hydrochloride (a derivative of Naftifine) is reported as an ingredient of Exodril in the following countries:

• Israel

International Drug Name Search

Prevacid

Prevacid is a brand name of lansoprazole, approved by the FDA in the following formulation(s):

PREVACID (lansoprazole - capsule, delayed rel pellets; oral)

• 
  Manufacturer: TAKEDA PHARMS NA
  
  Approval date: May 10, 1995
  
  Strength(s): 15MG ^[AB], 30MG ^[RLD][AB]

PREVACID (lansoprazole - tablet, delayed release, orally disintegrating; oral)

• 
  Manufacturer: TAKEDA PHARMS NA
  
  Approval date: August 30, 2002
  
  Strength(s): 15MG ^[AB], 30MG ^[RLD][AB]

Has a generic version of Prevacid been approved?

A generic version of Prevacid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Prevacid and have been approved by the FDA:

lansoprazole capsule, delayed rel pellets; oral

• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: October 15, 2010
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]


• 
  Manufacturer: MATRIX LABS LTD
  
  Approval date: November 10, 2009
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: April 23, 2010
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: November 10, 2009
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]

lansoprazole tablet, delayed release, orally disintegrating; oral

• 
  Manufacturer: TEVA PHARMS
  
  Approval date: October 15, 2010
  
  Strength(s): 15MG ^[AB], 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevacid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Rapidly disintegratable multiparticular tablet
  Patent 5,464,632
  Issued: November 7, 1995
  Inventor(s): Cousin; Gerard & Bruna; Etienne & Gendrot; Edouard
  Assignee(s): Laboratoires Prographarm
  Rapidly disintegratable multiparticulate tablet the excipient mixture of which is suitable for imparting a disintegration rate such that the tablet disintegrates in the mouth in an extremely short time, notably in less than sixty seconds, characterized by the fact that the active substance is present in the form of coated microcrystals or coated or uncoated microgranules.
  
  Patent expiration dates:
  
  
  • November 7, 2012
    
  
  
  
  • May 7, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Orally disintegrable tablets
  Patent 6,328,994
  Issued: December 11, 2001
  Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
  Assignee(s): Takeda Chemical Industries, Ltd.
  An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
  
  Patent expiration dates:
  
  
  • May 17, 2019
    
  
  
  
  • November 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Rapidly Disintegrable solid preparation
  Patent 7,399,485
  Issued: July 15, 2008
  Inventor(s): Shimizu; Toshihiro & Sugaya; Masae & Nakano; Yoshinori
  Assignee(s): Takeda Pharmaceutical Company Limited
  A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.
  
  Patent expiration dates:
  
  
  • May 26, 2018
    
    ✓ 
    Drug product
  
  
  
  • November 26, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Orally disintegrable tablets
  Patent 7,431,942
  Issued: October 7, 2008
  Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
  Assignee(s): Takeda Pharmaceutical Company Limited
  An orally disintegrable tablet of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
  
  Patent expiration dates:
  
  
  • May 17, 2019
    
    ✓ 
    Drug product
  
  
  
  • November 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Orally disintegrable tablets
  Patent 7,875,292
  Issued: January 25, 2011
  Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
  Assignee(s): Takeda Pharmaceutical Company Limited
  An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
  
  Patent expiration dates:
  
  
  • May 17, 2019
    
    ✓ 
    Drug product
  
  
  
  • November 17, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 28, 2011 - INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
  
  
  • April 28, 2012 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Prevacid Consumer Information (Drugs.com)
• Prevacid Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Prevacid Powder Packet Consumer Information (Wolters Kluwer)
• Prevacid Consumer Information (Cerner Multum)
• Prevacid Advanced Consumer Information (Micromedex)
• Lansoprazole Consumer Information (Drugs.com)
• Lansoprazole Consumer Information (Wolters Kluwer)
• Lansoprazole Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Lansoprazole Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Lansoprazole Powder Packet Consumer Information (Wolters Kluwer)
• Lansoprazole Consumer Information (Cerner Multum)
• Lansoprazole Advanced Consumer Information (Micromedex)
• Lansoprazole AHFS DI Monographs (ASHP)

Domperidon EB

Domperidon EB may be available in the countries listed below.

Ingredient matches for Domperidon EB

Domperidone

Domperidone maleate (a derivative of Domperidone) is reported as an ingredient of Domperidon EB in the following countries:

• Netherlands

International Drug Name Search

Hidrocortisona Biocrom

Hidrocortisona Biocrom may be available in the countries listed below.

Ingredient matches for Hidrocortisona Biocrom

Hydrocortisone

Hydrocortisone is reported as an ingredient of Hidrocortisona Biocrom in the following countries:

• Argentina

International Drug Name Search

Tevax

Tevax may be available in the countries listed below.

Ingredient matches for Tevax

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Tevax in the following countries:

• Ireland

International Drug Name Search